Biomerica Board of Directors Adds New Member<>tp://AllSpaces.co
NEWPORT BEACH, California, May 2, 2007 – Biomerica, Inc. (OTC BB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, today announced that its board of directors has increased the size of the board from four to five members and elected Jane F. Emerson, M.D., Ph.D., 52, Chief of Clinical Pathology and Vice-Chair for Clinical Affairs, Department of Pathology and Laboratory Medicine University of California, Irvine, to the board.
“Dr. Emerson’s understanding and foresight in the diagnostics’ market is very impressive,” said Biomerica chairman Zack Irani. “With her rich entrepreneurial, clinical and medical background, she will be a tremendous addition to our board.”
“There are very few companies the size of Biomerica that have the potential to make an impact in consumer healthcare,” Dr. Emerson said. “I look forward to working with Biomerica as a board member to help shape the direction of the company as it continues to grow.”
Dr. Emerson has received numerous honors, including an NIH Fellowship in Mechanisms of Insulin Action; grants including Investigator for Alzheimer’s Disease Research Center, NIH and has been a reviewer in journals including the Journal of Cancer Prevention and Detection. Dr. Emerson is the author of 4 patents and has presented or published over 28 articles/papers in the diagnostic field.
About Biomerica (OTCBB: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global medical technology company, based in Newport Beach, CA. The Company manufactures and markets advanced diagnostic products used at home, in hospitals, and in physicians’ offices for the early detection of medical conditions and diseases.
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking; such as statements relating to intended launch dates, sales potential, significant benefits, market size, growth of business, favorable positions, expansion, expected orders, leading market positions, anticipated future revenues or production volume of the Company, success of product and new product offerings. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, and accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. The potential risks and uncertainties include, among others, fluctuations in the Company’s operating results due to its business model and expansion plans, downturns in international and or national economies, the Company’s ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company’s dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.